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In this article, two arguments will be provided, based on both
clinical data and mathematical insights on the dynamics of the
leukemic cell population, to highlight the substantial effect that
imatinib also seems to have on the leukemic stem cells (LSCs).
The hypothesis proposed here is that imatinib may be able to
affect the LSCs in the same way it affects all other leukemic
cells, that is, by inhibiting their proliferation and consequently
causing them to reach their life span and die out. This is, indeed,
the general consensus on the effect that the drug has on
leukemic non-stem cells.
1–4 In fact, the different lifespans in the
hierarchical structure of the leukemic cell population can
explain the seemingly different (short-term) outcomes observed
among the various types of leukemic cells under imatinib,
rather than a differential effect of the drug on them. The latter
has been a typical point of view expressed in the literature on
chronic myeloid leukemia (CML), see, for example, Sloma et al.
2
I believe this represents an example of the usefulness of
combining mathematical modeling with the experimental and
clinical data to obtain a deeper understanding of the biological
system under consideration and its dynamics.
CML is a cancer of the white blood cells characterized by a
chromosomal translocation between chromosomes 9 and 22
known as the ‘Philadelphia chromosome’, which creates the
fusion gene BCR–ABL. The resulting protein, a tyrosine kinase,
yields growth factor independence, increased proliferation,
genetic instability and suppression of apoptosis in leukemic
cells.
3 Imatinib (Gleevec/Glivec; formerly STI571, Novartis, East
Hanover, NJ, USA) is a potent inhibitor of the BCR–ABL tyrosine
kinase and today is the standard ﬁrst-line therapy for patients
with newly diagnosed CML in chronic phase. This drug acts by
blocking the ATP-binding site of BCR–ABL, thus inhibiting the
enzyme activity and its downstream signaling (see Hochhaus
et al.
3 and the references therein). Imatinib has proven to be very
effective in reducing the total leukemic cell burden, as
measured by cytogenetic analysis. Data coming from the
International Randomized Study of Interferon vs STI571 Trial
(IRIS) for patients with newly diagnosed CML in chronic phase
show that, under imatinib, the estimated rate of a major
cytogenetic response at 18 months is 87.1%, whereas the
estimated rate of a complete cytogenetic response at 18 months is
76.2%.
5 This large decline in the leukemic burden can also be
observed using reverse transcriptase-PCR, a more sensitive
methodology that measures the levels of BCR–ABL transcripts.
For example, the data in Michor et al.
4 show that on average, after
about 3 months from the start of the treatment, a 100-fold decline
in the leukemic cell population is reached among patients.
There is evidence, however, indicating that imatinib may not
be able to completely eradicate the disease, even in patients
responding well to the therapy and for whom the vast majority
of leukemic cells died in the ﬁrst months of the treatment. One
of the most convincing arguments in favor of this hypothesis is
given by the following observation. After prolonged treatment,
if imatinib is removed from these patients, the disease will often
relapse and will quickly reach levels at or beyond the
pretreatment baseline.
4,6 Note that these relapses may be
observed in patients where there is no evidence of drug
resistance development, the presence of which could otherwise
explain the events. Indeed, after the relapse occurs, the patient
will typically respond well to the reintroduction of imatinib,
6 an
impossible event if the CML clone causing the relapse were to
be drug resistant. What then is causing these relapses? Clearly,
some leukemic burden must still be present, notwithstanding
imatinib. In fact, a minimal residual disease remains usually
detectable by reverse transcriptase-PCR even after many years of
treatment.
7 Importantly, it has been shown that this residual
disease is associated with the presence of primitive LSCs.
1,2
Evidence, both in vitro and in vivo, seems to indicate that this
small sub-population of LSCs is insensitive, that is, unresponsive
to imatinib.
1,2,4 This appears to be a rather common, established
point of view in the CML literature.
2 A mathematical model,
4
which includes among its assumptions the hypothesis that LSCs
cannot be depleted, has been occasionally referred to support
this hypothesis. To the contrary, it is this author’s opinion
that, given the data available today, the substantial effect that
imatinib also has on the LSCs should be recognized. To support
my statement, I will provide the following two arguments, based
on both clinical data and mathematical insights on the dynamics
of the leukemic cell population.
(1) Data coming from the IRIS Study show that generally the
disease is kept under control by imatinib if the treatment is
not discontinued, and as long as there is no development of
drug resistance.
3 This observation seems to imply that,
under treatment, the residual population of LSCs is not
growing in number. If it did grow, then we would also
expect to observe the growth of the associated minimal
residual disease, on average, among patients. However, the
opposite occurs: clinical data indicate that the incidence of
patients under imatinib with undetectable BCR–ABL levels
(complete molecular response (CMR)) grows, on average,
with time.
6,7 Although the relationship between the LSC
compartment and the minimal residual disease is not
completely understood, there should be a direct connection
between the two. That the LSC compartment may have
stopped growing during treatment should imply that
imatinib has also been able to affect the LSCs, given that
the LSC compartment was certainly growing before treat-
ment began, otherwise there would be no disease, and
probably going through many symmetric renewals, as we
estimated in Tomasetti et al.
8
(2) A stronger argument is the following. Note that long-lived
drug resistance will only be caused by those long-lived cells
that have the ability of self-renewal, that is, the stem-like
cells. Thus, for the problem of drug resistance, we may
focus only on them.
8 Assume now that, contrary to
intuition, the dynamics of the minimal residual disease, as
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reﬂect at all the dynamics of the LSC compartment and that
the LSCs are still dividing and growing in number even
under imatinib. Then we should be able to observe cases of
patients relapsing at any given time during treatment,
because of the development of drug resistance due to the
random point mutation mechanism, which is always acting
on each cell division. Actually, if we assume a growing
LSC population, then these occurrences should even
increase with time. Now, it has been estimated that it takes
approximately 5–7 years for CML to reach detection size.
4
Thus, if random point mutations causing drug resistance
could happen during treatment, due to the continuing
divisions of LSCs, then we should see various cases of
patients having relapses well after 5 years from the start of
the therapy, and even increasingly so, until when possibly
all patients under study have relapsed, as can be calculated
using the formula in Tomasetti et al.
8 However, this is again
in stark contrast with the available data.
3 As we can see in
Figure 1, relapses due to drug resistance seem to stop
occurring B5 years into the treatment. Note how the ‘curve’
for the various events (which include relapses) peaks at
around 2 years into treatment and then approaches zero at
4–5 years. Importantly, only a relatively small fraction of
patients did have a relapse due to drug resistance (less than
15%).
3 This curve is far from the shape we would observe
for the case where the LSCs were able to proliferate during
treatment, a scenario that is depicted in Figure 2, where the
expected relapsesFusing the formula in Tomasetti et al.
8
with realistic parameters’ valuesFare plotted against the
actual clinical data. Note that the bad ﬁt of the estimated
relapses to the actual data, for the ﬁrst years, is due to the
fact that, for simplicity, the estimate used did not include
the variability, among patients, given by the time of disease
detection, initial tumor load and its growth rate. Indepen-
dently of this limitation, the essential difference between the
hypothesis of drug-insensitive LSCs and the data is clearly
captured in the long -term outcome. Thus, if the LSC
compartment is not growing under imatinib, could it be that
the number of LSCs stabilizes after the treatment starts (for
example, due to the inability of imatinib to deplete the LSCs
or due to a saturation level) rather than contracting? Using
the previously mentioned formula,
8 it can be shown that for
the case where the populations were not contracting, we
would have a small percentage of the patients under
treatment relapsing every year during the study (unless the
LSCs were to be eternal). The fact that this is also contrary to
the evidence provided by the available clinical data
(Hochhaus et al.
3 and later reports from the IRIS Study),
indicates that, overall, the LSCs should not be dividing
under imatinib, but rather should slowly die out, otherwise
drug resistance would still be able to develop.
To summarize, the above two arguments seem to indicate
that, overall, the LSC compartment is not growing under
treatment, because imatinib has been able to affect these cells
by blocking their proliferation. Actually, they also provide some
evidence for an LSC compartment that is slowly shrinking in size
under imatinib. If imatinib were able to block the LSCs from
proliferating, these cells should not be able to do anything but
reach their lifespan and die, causing the LSC compartment to
slowly die out. This seems to be supported by the clinical data, if
there is any relationship between the surviving LSC population
at a given point in time and the amount of Philadelphia-positive
cells and BCR–ABL levels found at that time. In fact, the data
clearly indicate that the percentage of patients under imatinib
who are in complete cytogenetic response and/or CMR is
generally increasing over time.
7 Furthermore, relapses due to
drug resistance stop occurring, a reﬂection of the fact that the
LSC population is not proliferating anymore but rather shrinking
over time. Importantly, the potential ability of imatinib to slowly
induce the elimination even of the LSC population is also
suggested by recent data demonstrating that a certain percen-
tage of patients, who achieve and keep CMR, have been able to
discontinue imatinib without relapsing.
6
The hypothesis proposed here is, therefore, that imatinib may
be able to affect the LSCs in the same way, at least qualitatively,
it affects all other leukemic cells. Indeed, the ability of imatinib
to inhibit proliferation of the leukemic cells consequently
causing them to slowly die out is in accordance with the
general consensus in the medical literature regarding the effect
that the drug has on leukemic non-stem cells.
1–4 Thus, this
hypothesis simply extends the effects of imatinib also to include
the LSC compartment. After all, it has not been biologically
explained why a targeted drug, which is able to bind to the ATP-
binding site of BCR–ABL in a leukemic cell, would not be able
to have the same effect on its mother stem cell. This fact also
explains why point mutations in the BCR–ABL domain can
cause resistance to imatinib. If imatinib were not able to bind to
the ATP-binding site of BCR–ABL in a LSC, we would not have a
distinction between drug-resistant LSCs and not-resistant LSCs,
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Figure 1 Data from the IRIS Study. Events are as follows acute phase,
blast crisis, loss of complete hematologic response (CHR), major
cytogenetic response or death (based on Figure 2 in Hochhaus et al.
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Figure 2 Data from the IRIS Study (bars) versus estimated annual
rates of relapses due to drug resistance (line with dots).
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resistance caused by random genetic mutations.
Note that this hypothesis does not contradict the experimental
evidence indicating the apparent inability of imatinib to
eliminate the LSCs within a certain time frame.
Indeed, the observed decline of the leukemic cells is due
to imatinib blocking their proliferation rather than killing them:
the leukemic cells can then only reach their lifespan and
die. Given that all blood cells are relatively short-lived (days to
several months, depending on the type of cell), with the
exception of the stem cells, all such cells will die out relatively
quickly, leaving only the long-lived LSCs as a residue. Therefore,
the different lifespans of the various types of leukemic cells can
potentially explain what leads to different (short-term) outcomes
in the experimental observations, rather than assuming a
differential effect of the drug on the various types of leukemic
cells. In fact, by simple calculations, we can grossly estimate
that on average, among patients, the LSCs are able to survive for
at least 10 years. This large difference in the lifespan among
the cells of the blood hierarchical system is sufﬁcient to explain
the observed experimental and clinical data. We leave to a
future work a more precise estimation, which would have the
potential to indicate the average time needed to eradicate
the disease using imatinib. In mathematical terms, the average
dynamics of the LSC compartment before treatment could
be described by the equation S0(t)¼(L0(1 a 2b) D0)S(t) (see
Tomasetti et al.
8 for a detailed explanation), the next compart-
ment (say progenitors) by N 0
1(t)¼(L0(aþ2b))S(t) (L1þD1)N1(t),
whereas all other compartments by equations of the form
N 0
i(t)¼2Li 1Ni 1(t) (LiþDi)Ni(t), i¼2,y,n,w h e r enþ1i s
the total number of compartments in the hematopoietic system.
The effect of imatinib would then be to reduce to very low values
(possibly zero) the division rates Li of all types of cells. There is
also the possibility that imatinib could even increase the
death rates Di of the leukemic cells (for example, by attenuating
the apoptosis inhibition caused by BCR–ABL), but clear evidence
is lacking.
In conclusion, imatinib seems to affect the LSCs in the same
way it affects all other leukemic cells; however, the different
lifespans of the various types of leukemic cells lead to different
(short-term) outcomes in the experimental and clinical observa-
tions. This hypothesis, which has been formulated on the basis
of experimental evidence, clinical data and mathematical
insights on the dynamics of CML, seems to explain the current
clinical data on CML better than previous assumptions, which
appear to contradict at least some of the evidence available
today on CML. The proposed hypothesis is indeed able to both
elucidate the reasons behind the quick contraction in the
leukemic burden occurring after starting the treatment, due to
cells with relatively short lifespan whose proliferation has been
inhibited, as well as to explain why the disease is not completely
eliminated typically at least for some years. This is due to the
surviving LSCs, which are not killed but rather are very slowly
dying out under the inhibitory effect of imatinib. It would
also explain why there is no clear evidence of relapses due to
drug resistance caused by random point mutations originated
during treatment. Furthermore, if the treatment is discontinued
before the LSC sub-population is completely eradicated, then a
relapse will be observed, caused by the surviving LSCs resuming
their cycling activity, while otherwise a potentially complete
cure would be the expected outcome.
6
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